Skip to main content
Premium Trial:

Request an Annual Quote

Avesthagen to Build Genomic Database of Parsi Population

NEW YORK (GenomeWeb News) - An Indian biotech company plans to work with other partners to create a genomic database of the Parsi Zoroastrians, small, relatively genetically homogeneous population. 
 
Avestha Gengraine of Bangalore said last week it will use genomic analyzers from Sequenom and Applied Biosystems' sequencers on samples collected from the community to "build a complete genetic, genealogical and medical database of the Parsis."
 
The company also said it will use its bioinformatic resources in the project, and will help fund it with seed capital.
 
Avesthagen said the Parsi population numbers around 69,000 in India, and has long discouraged marriage outside of the community.
 
The company said it hopes to use information drawn from the project, called AvestaGenome, for therapeutic ends in particular, because genetically isolated populations can offer more accurate links between genes and diseases. 
 
Avestha said the project is expected to cost around $28 million and may be complete in about five years. 

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.